A novel HBc-S230 protein chimeric VLPs induced robust immune responses against SARS-CoV-2

doi:10.1016/j.intimp.2024.113362

科研成果详情

题名	A novel HBc-S230 protein chimeric VLPs induced robust immune responses against SARS-CoV-2
作者	Feng, Weixu 1; Chen, Zhuo 2; Wu, Lianpeng 3; Chen, Xiuting2; Li, Qingfeng 2; Xiang, Yunru2; Guo, Yanru 2; Du, Wangqi2; Chen, Jun2; Zhu, Shanli2; Dong, Haiyan2; Xue, Xiangyang2; Zhao, Kong-Nan2,4; Zhang, Lifang2
发表日期	2024-12-25
发表期刊	International Immunopharmacology 影响因子和分区
语种	英语
原始文献类型	Article
关键词	COVID-19 HBc S protein SARS-CoV-2 Vaccine VLPs
其他关键词	PARTICLE VACCINE CANDIDATE ; RBD
摘要	Here, we report that four functional fragments of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spike protein including receptor binding motif (RBM), fusion peptide (FP), heptad repeat 1 (HR1) and heptad repeat 2 (HR2) were chosen to develop a recombinant S subunit protein vaccine. This recombinant protein consisting of S230 amino acids (aa) (S230) bound specifically to the antibody from COVID-19-patients serum, which showed very strong antigenicity. The S230 was then engineered to present on the surface of Hepatitis B core (HBc) virus-like particles (VLPs) to develop HBc-S230 chimeric VLPs vaccine. Both vaccines induced strong humoral and cellular immune responses in mice, however, HBc-S230 chimeric VLPs elicited significantly higher immunogenicity than the S230. HBc-S230 chimeric VLPs promoted to generate not only dramatically higher levels of S230-specific serum antibodies, but also marked higher CD4+/CD8 + T cells ratio and substantially higher yields of IFN-γ and IL-6. Furthermore, HBc-S230 chimeric VLPs induced serum antibodies that could effectively neutralize the infection with three SARS-CoV-2 pseudoviruses (Wild type, Delta and Omicron). Our results demonstrated that HBc-S230 chimeric VLPs immunization conveyed the humoral immunity, which lasted longer than six months. Clearly, HBc-S230 chimeric VLPs enhanced immunogenicity of the S230, which could provide potent and durable protection against SARS-CoV-2 infection, indicating that HBc-S230 chimeric VLPs possessed great potential for developing highly immunogenic vaccines against SARS-CoV-2.
出版者	ELSEVIER
ISSN	1567-5769
EISSN	1878-1705
卷号	143 期号:Pt 2
DOI	10.1016/j.intimp.2024.113362
页数	10
WOS类目	Immunology ; Pharmacology & Pharmacy
WOS研究方向	Immunology ; Pharmacology & Pharmacy
WOS记录号	WOS:001339513600001
收录类别	SCOPUS ; PUBMED ; SCIE
URL	查看原文
PubMed ID	39426233
SCOPUSEID	2-s2.0-85206665996
通讯作者地址	[Xue, Xiangyang]Institute of Molecular Virology and Immunology,Department of Microbiology and Immunology,School of Basic Medical Sciences,Wenzhou Medical University,Zhejiang,Wenzhou,China
Scopus学科分类	Immunology and Allergy;Immunology;Pharmacology
SCOPUS_ID	SCOPUS_ID:85206665996
TOP期刊	TOP期刊
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/220906
专题	基础医学院（机能实验教学中心）_病原生物学与免疫学系检验医学院（生命科学学院、生物学实验教学中心）
通讯作者	Xue, Xiangyang; Zhao, Kong-Nan; Zhang, Lifang
作者单位	1.School of Laboratory Medicine and Life Sciences,Wenzhou Medical University,Wenzhou,Zhejiang,China; Key Laboratory of Laboratory Medicine,Ministry of Education,Wenzhou Medical University,Wenzhou,Zhejiang,China; Institute of Molecular Virology and Immunology,Department of Microbiology and Immunology,School of Basic Medical Sciences,Wenzhou Medical University,Zhejiang,Wenzhou,China; 2.Institute of Molecular Virology and Immunology,Department of Microbiology and Immunology,School of Basic Medical Sciences,Wenzhou Medical University,Zhejiang,Wenzhou,China; 3.Department of Laboratory Medicine,The Sixth People Hospital of Wenzhou,Zhejiang,Wenzhou,China; 4.Australian Institute for Bioengineering and Nanotechnology,The University of Queensland,St Lucia,Australia
第一作者单位	检验医学院（生命科学学院、生物学实验教学中心）
通讯作者单位	基础医学院（机能实验教学中心）_病原生物学与免疫学系
第一作者的第一单位	检验医学院（生命科学学院、生物学实验教学中心）
推荐引用方式 GB/T 7714	Feng, Weixu,Chen, Zhuo,Wu, Lianpeng,et al. A novel HBc-S230 protein chimeric VLPs induced robust immune responses against SARS-CoV-2[J]. International Immunopharmacology,2024,143(Pt 2).
APA	Feng, Weixu., Chen, Zhuo., Wu, Lianpeng., Chen, Xiuting., Li, Qingfeng., ... & Zhang, Lifang. (2024). A novel HBc-S230 protein chimeric VLPs induced robust immune responses against SARS-CoV-2. International Immunopharmacology, 143(Pt 2).
MLA	Feng, Weixu,et al."A novel HBc-S230 protein chimeric VLPs induced robust immune responses against SARS-CoV-2".International Immunopharmacology 143.Pt 2(2024).